Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist https://alluvi043978.keepwritingblog.com/653873/alluvi-a-thorough-dive-into-the-drug-s-promise